RSC Advances

RSC Advances

www.rsc.org/advances

ROYAL SOCIETY OF CHEMISTRY

www.rsc.org/advances

RSC Advances

Full Paper

Coating of carboxymethyl dextran on liposomal curcumin to improve the anticancer activity†

Qiyu Huang, Lili Zhang, Xiaoyi Sun, Ke Zeng, Juan Li* and You-Nian Liu*

In this work, carboxymethyl dextran (CMD), a polysaccharidic dextran derivative with well-known biocompatibility and biodegradability, was used to modify curcumin-loaded liposomes for improving the anticancer efficacy of curcumin. The CMDylated curcumin-loaded liposomes (CMD-Cur-Lip) were successfully prepared and characterized in comparison with unmodified and two PEGylated curcumin-loaded liposomes. The results showed that: 1) the encapsulation efficiency of curcumin
10 in the liposomes was improved after being modified with CMD; 2) all the curcumin-loaded liposomes displayed controlled release characteristics; 3) the CMD-Cur-Lip demonstrated improved cell cytotoxicity against cancer cells, as compared to other liposomal formulations and free curcumin; 4) CMD-Cur-Lip exhibited the highest cellular uptake as compared to other liposomal formulations.

Introduction

15 Curcumin is a natural polyphenol used for chemoprevention of multiple cancers by modulating multiple molecular pathways involving interference of tumor initiation, restriction of tumor progression, inhibition of invasion/metastasis of cancer cells and promotion of apoptosis.[1] Nevertheless, the clinical application of
20 curcumin is greatly hampered by its poor aqueous solubility therefore resulting in poor bioavailability.[2] To overcome these limitations, nanoformulation of curcumin based on carriers such as biodegradable polymeric nanoparticles, micelles and liposomes, have been investigated.[3]
25 Liposomes, due to their excellent biocompatibility and abilities to encapsulate and transport various molecules, are widely used in drug delivery, gene transfection and biosensing fields.[4] Up to date, drug-carrying liposomes and modified liposomal nanoparticles are commercialized to treat certain cancers. For
30 instance, PEGylated liposome-based doxorubicin (Doxil®) has been clinically approved in the treatment of ovarian cancer, AIDS-related Kaposi's sarcoma and multiple myeloma.[5] Recently, liposomal curcumin has attracted a lot of attention. For example, curcumin-encapsulated liposome was found to suppress growth
35 of head and neck squamous cell carcinoma both *in vitro* and *in vivo* via an AKT-independent pathway.[6] Arab-Tehrany and coworkers reported a salmon lecithin based nanoliposomes for curcumin encapsulation to achieve improved curcumin bioavailability, as well as *in vitro* cytotoxicity through a real-time
40 cell impedance monitoring.[7]

For prolonged blood circulation and increased cellular uptake, modifications of the liposomal curcumin were employed, among which PEGylation[8] and chitosan coating[9] are commonly used. Herein, we introduced
45 an ameliorative modification to liposomal curcumin using carboxymethyl dextran (CMD). CMD, an anionic

polysaccharidic derivative, possesses good biocompatibility, biodegradability, low immunogenicity and low toxicity.[10] Our group has established an effective loading and controlled
50 release of doxorubicin by CMD-coated liposomes.[11] In this work, CMD was coated onto the liposomal curcumin through the attachment of a hydrophobic alkyl chain to CMD. Furthermore, PEGylated liposomes were also synthesized and compared with CMDylated liposomes in ways of
55 encapsulation efficiency, curcumin release profile, cellular uptake and cell cytotoxicity.

Experimental

Materials

LIPOID E 80 (egg phospholipids with 80% phosphatidylcholine,
60 agglomerates) was purchased from Shanghai Toshisun Biology & Technology Co., Ltd. (Shanghai, China). Cholesterol was purchased from Sangon Biotech. (Shanghai, China). Bromoacetic acid was obtained from Bio Basic Inc. PEG10000 (MW 10000) and mPEG2000 (MW 2000) were purchased from Fluka.
65 Oleylamine, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC), and *N*-hydroxysuccinimide (NHS) were purchased from Sigma-Aldrich. Curcumin (Cur, >98%) was purchased from Aladdin. Dextran-T10 of 10 kDa was purchased from Pharmacia AB (Uppsala, Sweden). Other materials were obtained from
70 commercial sources.

Synthesis of CMD-OA, mPEG-OA and PEG-OA

Detailed synthesis of all the compounds were described in Electronic Supplementary Information (ESI)†. The synthesis of CMD-OA was similar to our previous work.[11, 12] Synthesis of
75 mPEG-oleylamine (mPEG-OA) and PEG-oleylamine (PEG-OA) was based on Li and McLean's method.[13] The contents of residual carboxyl groups in CMD-OA were measured by acid-base

titration method, which were found to be 0.50 mmol [-COOH]/g. The contents of carboxyl groups in PEG-OA were also measured by acid-base titration method, found to be 0.26 mmol [-COOH]/g.

Preparation of curcumin-loaded liposomes

In this work, four different curcumin-loaded liposomes, namely unmodified curcumin-loaded liposomes (Cur-Lip), PEGylated curcumin-loaded liposomes (PEG-Cur-Lip and mPEG-Cur-Lip) and CMDylated curcumin-loaded liposomes (CMD-Cur-Lip), were prepared according to the reported procedures.[14] To be specific, exact 40 mg of LIPOID E 80, 5 mg of cholesterol, 2 mg of curcumin and 2 mg of modifying agent (PEG-OA, mPEG-OA and CMD-OA for PEG-Cur-Lip, mPEG-Cur-Lip and CMD-Cur-Lip, respectively) were weighed and dissolved in chloroform/methanol (2:1, v/v) mixture solution. After sonication for 10 min, the organic solvents were removed by rotary evaporation, followed by 10 min N_2 gas sweeping. The resultant yellow thin film was hydrated with 10 mL PBS (10 mM, pH 6.8) at 60 ^{o}C, with manual shaking until no obvious suspended particles were observed. Finally, the solution was sonicated to obtain the products. Blank liposomes were also prepared as described above except for the addition of curcumin.

Encapsulation efficiency

The encapsulation efficiency (EE%) was measured by UV-Vis on a Shimadzu UV-2450. Curcumin-loaded liposomes were centrifuged at 7000 rpm for 5 min and 50 μL of supernatant were taken and dissolved in 2.5 mL of anhydrous ethanol. Absorbance at 425 nm was measured by UV-Vis and the concentration of loaded curcumin was calculated from the calibration curve. The encapsulation efficiency was obtained from the equation:

Encapsulation efficiency (%) = Loaded curcumin/Initial curcumin × 100

Calibration curve was obtained by plotting absorbance at 425 nm against curcumin concentrations of 2.0, 3.0, 4.0, 5.0, 6.0, 8.0 μg/mL. Here, a linear equation was fitted as: $A_{425} = 0.154C - 0.00204$, $R^2 = 0.997$.

Fluorescence spectroscopy

To verify the insertion of curcumin into the lipid bilayers, samples of curcumin-loaded liposomes were diluted with PBS (10 mM, pH 6.8) containing 0.5% (w/v) SDS to a final curcumin concentration of 2.44 μg/mL, according to the encapsulation efficiency. SDS was added to increase the solubility of free curcumin in PBS and such concentration was used so that liposome stability would not be influenced by SDS.[15] Free curcumin was dissolved in ethanol and then diluted by the above PBS/SDS into the same concentration as a control. The emission wavelength and fluorescence intensities of different samples were measured with excitation wavelength of 420 nm and scanning rate of 1200 nm/min (Hitachi, F-4600).

Size distribution and ζ-potential measurement

The size distribution and ζ-potential was analyzed by dynamic light scattering (DLS) technique using a Malvern Zetasizer Nano ZS (Malvern instruments, UK). The apparatus was equipped with a 4 mW He/Ne laser emitting 633 nm. The hydrodynamic diameters (D_h), polydispersity index (PdI) and ζ-potential were measured at a scattering angle of 173° and 25 ^{o}C. All measurements were conducted in triplicates.

Atomic force microscopy (AFM)

Morphological observation of CMD-Cur-Lip was performed on a Dimension V AFM instrument (Veeco, US). Sample was prepared by depositing 10 μL of diluted CMD-Cur-Lip (0.1 mg/mL) on a silica chip and letting dry for 72 h at room temperature in a desiccator containing silica gel.

In vitro release

The curcumin release profile from different liposomes was determined by dialysis method. The sample liposomes were centrifuged (7000 rpm, 5 min) to remove some possible insoluble curcumin and then 10 mL of the supernatant sample were dialyzed against 500 mL PBS/SDS solution. At certain time intervals, 3 mL of dialysis solution was taken out for analysis and fresh PBS/SDS solution was replenished. As for a complete curcumin release, dialysis solution would have a concentration of ~ 4 μg/mL curcumin but its absorbance at 425 nm would be about 0.02 in PBS/SDS using a 1-cm pathlength cuvette, so it is necessary to modify the UV-Vis assay for curcumin quantification. In order to enhance the UV-Vis absorbance, equal volume of anhydrous ethanol (3 mL) was added into 3 mL of the dialysis sample since the extinction coefficient for curcumin in PBS/SDS/ethanol is 10 times higher than that in PBS/SDS. Calibration curve was obtained by measuring A_{425} of free curcumin in PBS/SDS/ethanol and undergoing linear fitting. The cumulative release was calculated as follows:

Cumulative Release (%) = Released curcumin/Total curcumin × 100

Fluorescence microscopy

HeLa cell lines were obtained from the cell bank of Xiangya Hospital, Central South University (Changsha, China). HeLa cell lines were grown in DMEM medium (GIBCO) containing 10% FBS, 1% streptomycin and 1% penicillin. The cells were maintained at 37 ^{o}C in a humidified incubator with 5% CO_2. A 24-well plate was used and approximately 10^4 cells were seeded per well. When cell confluence reached ~60%, they were ready to uptake the liposomes. Cur-Lip, PEG-Cur-Lip, mPEG-Cur-Lip and CMD-Cur-Lip were added into the wells with a final curcumin concentration of 20 μg/mL and incubated in the same condition for 4 and 24 h, respectively. Cellular uptake was analyzed by measuring fluorescence emission from curcumin using an inverted fluorescence microscope (Nikon ECLIPSE TE2000U) equipped with a digital camera and a blue filter (λ_{ex} = 420–490 nm, λ_{em} = 490–560 nm). Images were captured with NIS Elements F 3.0 software (Nikon).

Flow cytometry

To better characterize cellular uptake of the liposomal curcumin, we performed flow cytometry assay for quantification. HeLa cell lines were incubated similarly to the fluorescence microscopy, the difference being that approximately 2×10^5 cells were needed per well. After incubation with all four curcumin liposomes for 4 h at

37 °C in a humidified incubator with 5% CO_2, cell culture was discarded and cells were digested by trypsin (GIBCO, 0.25%). Cells in each well were then harvested in 2 mL Eppendorf tubes and centrifuged at 8 000 rpm for 5 min, followed by washing
5 with 0.5 mL of 50 mM PBS (pH 7.4). Centrifugation and washing were repeated for three times and cells were finally suspended in 0.2 mL of PBS for flow cytometry measurement (BD, FACS 101). Untreated cells were used as blank control.

MTT assay

10 MTT-based assay was conducted to assess the killing-effects of different liposomes against cancer cells. In general, HeLa cells were harvested and cultured until reaching logarithmic phase. The cells were then suspended and diluted with cell culture solution to reach a final cell concentration of approximately 1×10^5 /mL. A
15 96-well plate was prepared and 100 µL of cell suspension was added into each well. The cells were incubated in 37°C thermal incubator containing 5% CO_2 for 24 h. The culture solution was then discarded and each well was filled with 100 µL drug/liposomes (curcumin, Cur-Lip, PEG-Cur-Lip, mPEG-Cur-
20 Lip and CMD-Cur-Lip) of different concentrations. Free curcumin was prepared by dissolving proper concentrations of free curcumin in DMSO. Incubation was performed for 48 h in the same condition. Twenty microliter of 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) in 2.5 mg/mL was
25 added into each well and incubated for another 5 h. After the incubation, all the solutions in the wells were drawn and 200 µL DMSO was added into each well to dissolve the formed crystals. The plate was placed into a microplate reader (Bio-Tek ELx800) and the UV-Vis absorbance was determined at 490 nm (corrected
30 for background absorbance at 630 nm).

In addition, the data of cell viability for each concentration are statistically compared between CMD-Cur-Lip and the other four samples individually using the Student's t-test in Microsoft Excel 2007. The level of significance used is $p < 0.05$.

35 ## Results and Discussion

Preparation and characterization of four liposomal curcumin

To increase the circulation of liposome, PEG coating is commonly utilized. Herein, CMD coating was applied to not only
40 increase the circulation, more importantly, increase the cellular uptake of liposomes. In order to study the difference between CMD coating and traditional PEG coating, both CMDylated and PEGylated liposomes were fabricated. Specifically, PEG of MW 10000 and mPEG of MW 2000 were used as control.
45 In order to coat mPEG, PEG and CMD onto the liposomal surface, chemical modification with lipid derivatives for an amphiphilic character was involved. After the EDC/NHS coupling, hydrophobic oleyl moieties were linked to the hydrophilic CMD and PEG molecules (ESI†). Then, the thin-lipid
50 film hydration method was applied to load the hydrophobic curcumin into the liposomes. All four curcumin-loaded liposomes have average hydrodynamic diameters (D_h) of 120-200 nm (Fig. 1). As confirmed by AFM, the particles of CMD-Cur-Lip are spherical (Fig. 2). The size of liposomes has a range from 50 to
55 60 nm, with an average height of 10 nm. The size determined by

Fig. 1. Size distribution of curcumin-loaded liposomes.

60 Fig. 2. AFM images of CMD-Cur-Lip.

Table 1. The encapsulation efficiency, hydrodynamic diameter (D_h) and ζ-potential of four curcumin-loaded liposomes

65

Sample	EE/%	D_h/nm	PdI	ζ-potential/mV
Cur-Lip	71.2	120.3±6.2	0.19±0.03	-5.01
mPEG-Cur-Lip	77.7	139.4±9.3	0.27±0.02	-5.04
PEG-Cur-Lip	81.5	184.1±12.1	0.34±0.05	-7.63
CMD-Cur-Lip	82.8	141.5±5.9	0.19±0.02	-8.58

AFM is much smaller than that by DLS, which might be caused by the different treatments during the tests. For AFM imaging, liposomal samples which were dried, could possibly collapse. On
70 the other hand, the size distribution of liposomes by DLS was measured in a hydrated state.

After removing the unloaded curcumin precipitate from the liposomal dispersion by centrifugation, the EE% was calculated. Interestingly, the EE% of CMD-Cur-Lip and PEG-Cur-Lip are
75 higher than those of PEG-Cur-Lip and unmodified Cur-Lip (listed in Table 1.). We also found higher EE% of CMD-Cur-Lip than those of other reported liposomal which were around 60-70%.[7, 16] The difference of EE% among the liposomes may be caused by the solubility of curcumin, and the stability of lipid components
80 in the solution. The increase of EE% suggests CMD-Cur-Lip and PEG-Cur-Lip have higher stability than the others because the unloading of curcumin could influence the aggregation and/or

fusion of liposomes. As reported, the solubility of curcumin in water is about 11 ng/mL,[17] the unloaded insoluble curcumin will precipitate in aqueous solution. As well, the liposomal suspension if not stabilized properly will undergo aggregation accompanying with insoluble curcumin. For CMD-Cur-Lip, CMD coating improves the stability of liposome and more curcumin could be well dispersed in the lipid layer, which is ascribed to the increase of EE%.

Fluorescent properties of liposomal curcumin

It was reported by Puvvada that once curcumin was loaded into niosome, a nonionic surfactant-based vesicle, the maximum emission wavelength λ_{max} would have a blue shift of around 50 nm due to its insertion into the lipid bilayer.[18] This characteristic is an important indicator of curcumin loading and unloading. In our work, the fluorescence emission of curcumin did have a ~ 30 nm shift after the curcumin encapsulation into the liposomes (Fig. 3). No obvious difference in emission wavelength was observed among the four liposomes, indicating that the liposomes probably encapsulated curcumin by the same mechanism of action. The blue shift suggests the presence of curcumin is transferred from the more polar region to liposomes containing less polar regions, consistent with other reported results.[18]


Fig. 3. Comparison of fluorescence emission wavelengths from free and loaded curcumin under excitation of 420 nm

In vitro release

As discussed above, curcumin is hardly soluble in water. In addition, curcumin is extremely unstable when pH > 7.[19] Due to the insolubility and instability of curcumin, the *in vitro* release experiment should be carefully carried out, especially for choosing the suitable release media, as also found by others.[20] It is noted that the solubility and stability of curcumin could be improved in some surfactants, in cell culture medium containing 10% fetal calf serum and in human blood.[20,21] In this work, the *in vitro* release of curcumin from the curcumin-loaded liposomes was measured in PBS/SDS (pH 6.8). PBS/SDS instead of PBS was used in order to keep the sink conditions which dissolved curcumin well. In addition, pH 6.8 was selected to lower the hydrolysis of curcumin. The results demonstrated that after 120 h of incubation, only 60% of the curcumin was released from CMD-Cur-Lip, 80-85% from mPEG-Cur-Lip and PEG-Cur-Lip, 90% from unmodified Cur-Lip (Fig. 4). While, most curcumin was released in the early 20 h for free curcumin. Generally, drug release is a complex process which is attributed to drug

physicochemical properties, drug diffusion, and carrier integrity. The sustained release of CMD-Cur-Lip indicates the CMD coating stabilizes the liposomes against the leakage of curcumin in circulation. Also, this biocompatible CMD shell could reduce the risk of clearance by the reticuloendothelial system (RES),[22] thus facilitating liposome accumulating at pathological sites via enhanced permeability and retention (EPR) effect.[23] Furthermore, it was found that CMD-Cur-Lip are stable for at least 72 h upon incubation with calf serum (data not shown). It suggests that CMD-Cur-Lip are more potent than other three liposomes upon the systemic administration.


Fig. 4. Cumulative release for curcumin alone and curcumin-loaded liposomes. Measurements were conducted in PBS (pH 6.8) at 37°C for 120 h.

Cellular uptake

To observe the differences of liposomal curcumin in intracellular delivery, the uptake of Cur-Lip, CMD-Cur-Lip, PEG-Cur-Lip and mPEG-Cur-Lip by HeLa cells was determined by reverted fluorescence microscope, respectively. HeLa cells were treated with the same concentration of each curcumin-loaded liposomes, and the accumulation of curcumin in the cells was imaged after 4 h and 24 h, respectively. The results showed that after exposing for 1 s, cells incubated with all four liposomes generated decent fluorescence, among which unmodified Cur-Lip had a bit lowered fluorescent intensity compared with the other three (Fig. 5). This result clearly indicated the modification of either CMD or PEG helps the internalization of the liposomes into the cells. However, after 24 h incubation, even with increased exposure time (10 s), curcumin in the cells incubated with Cur-Lip became undetectable (Fig. 5A). PEGylated curcumin-loaded liposomes (mPEG-Cur-Lip and PEG-Cur-Lip) exhibited weakened curcumin accumulation (Fig. 5C and D), while CMD-Cur-Lip showed the strongest fluorescence intensity (Fig. 5B), expressing the greatest ability in delivering curcumin into HeLa cells and keeping the drug from leaking out of the cells, therefore inducing a prolonged and sustained drug treatment. The feature of enhanced intracellular uptake of CMDylated liposomes may be resulted from the facts that CMDylated liposomes selectively favor tumor cell-type and that the three-dimensional dextran hydroxyl network shell points to the endocytotic mechanisms of uptake.[24]

To quantify the uptake efficiency of loaded curcumin into the cells, flow cytometry was conducted with excitation wavelength of 488 nm and emission wavelength of 520 nm. As seen in Fig. 6

Fig. 5. Observation of fluorescence of HeLa cells treated by Cur-Lip (A), CMD-Cur-Lip (B), mPEG-Cur-Lip (C), and PEG-Cur-Lip (D). The pictures in the left show the cells incubated for 4 h
5 with 1 s exposure and the pictures in the right column show the cells incubated for 24 h with 10 s exposure.


Fig. 6. Flow cytometric measurement of curcumin uptake by HeLa cells after incubation with Cur-Lip, PEG-Cur-Lip, mPEG-
10 Cur-Lip and CMD-Cur-Lip.

untreated cells showed the weakest fluorescence emission with only 4.76% of cells gated in the positive zone. Cur-Lip, PEG-Cur-Lip and mPEG-Cur-Lip showed relatively stronger
15 fluorescence intensity with 14.02%, 56.12% and 61.19% of cells gated, respectively. CMD-Cur-Lip generated the strongest


Fig. 7. Cell viability of HeLa cells as a function of curcumin concentration. Asterisks indicate significant differences ($p < 0.05$).

20

Fig. 8. Cell viability of HeLa cells treated with blank liposomes as a function of lipid concentration. Axis of coordinates herein is expressed in the values of curcumin concentration in Fig. 7 for comparing with the corresponding cytotoxicity of control
25 liposomal curcumin.

fluorescence intensity with 92.99% of cells above the gate line, indicating the highest cellular uptake. Furthermore, the curcumin uptake amounts (calculated by the geometric mean
30 of the fluorescence intensity) of CMD-Cur-Lip was about 3.7-fold higher than that of unmodified Cur-Lip, and about two-fold over those of mPEG-Cur-Lip and PEG-Cur-Lip. These results quantitatively supported the above visualization of cellular uptake by inverted fluorescence microscope, being a
35 strong proof of enhanced cellular uptake by CMD coating. The enhanced cellular uptake of curcumin could be favorable for their anticancer activity, as demonstrated by others and our previous studies.[25]

Cell cytotoxicity

40 To determine whether the encapsulation of curcumin into modified or unmodified liposomes could enhance the anticancer activity, cell viability of HeLa cells were analyzed after curcumin or curcumin-loaded liposomes treatment. The results showed that liposomal encapsulation enhanced the
45 cytotoxicity of curcumin towards the cancer cells (Fig. 7). With the increase of curcumin concentration, all groups showed higher cytotoxicities, among which CMD-Cur-Lip exhibited the strongest cytotoxicity. To be exact, the IC_{50} of Cur-Lip was ~15.6 μM. Treatments with PEG-Cur-Lip,

mPEG-Cur-Lip and CMD-Cur-Lip led to a lowered IC_{50} of ~13.1 μM, ~11.4 μM and ~6.6 μM, respectively, showing a greatly improved cytotoxicity as compared with free curcumin (IC_{50}: ~24.8 μM). As derived from the statistical analysis, there are significant differences between cytotoxicity of CMD-Cur-Lip and those of other three curcumin-loaded liposomes and free curcumin at the high curcumin concentrations (20 μM and 50 μM). Therefore, CMD-Cur-Lip significantly enhanced the inhibition of tumor cell growth. To further support our findings, the cytotoxicity of blank liposomes (Lip, PEG-Lip, mPEG-Lip and CMD-Lip) were also tested (Fig. 8). The stock solutions of blank liposomes were prepared exactly according to the procedure of curcumin-loaded liposomes, except for the absence of curcumin. The stock solution was then serial-diluted in the same multiples so that the lipid concentration of blank liposomes remained the same as used in the previous MTT assay. It was revealed that no significant differences among the cytotoxicity of the blank liposomes at all the concentrations studied. This result strongly suggests cytotoxicity of CMD-Cur-Lips shown in the MTT assay was the outcome of the enhanced curcumin intracellular uptake by the cancer cells.

Conclusion

In brief, this work has shown that CMD coating on liposomal curcumin improves the cytotoxicity of curcumin against cancer cells by enhancing the sustained release and cellular uptake. Moreover, the residual carboxyl groups on the CMD layer also allow for further modifications such as targeting ligands. These characteristics render the CMD-Lip a potential vector for the encapsulation of other hydrophobic antitumor drugs, with which further studies are underway.

Acknowledgement

Notes and references

College of Chemistry and Chemical Engineering, Central South University, Changsha, Hunan 410083, China.
Fax: 86-731-8887 9616; Tel: 86-731-8883 6964;
E-mail: juanli@csu.edu.cn; liuyounian@csu.edu.cn
† Electronic Supplementary Information (ESI) available: [Synthesis and characterization of CMD-OA, mPEG-OA, and PEG-OA]. See DOI: 10.1039/b000000x/‡

1   (a) S. S. Dhule, P. Penfornis, J. B. He, M. R. Harris, T. Terry, V. John and R. Pochampally, *Mol. Pharm.*, 2014, **11**, 417; (b) W. Park, A. Amin, Z. G. Chen and D. M. Shin, *Cancer Prev. Res.*, 2013, **6**, 387; (c) R. L. Thangapazham, A. Sharma and R. K. Maheshwari, *AAPS J.* 2006, **8**, E443.

2   S. Jambhrunkar, S. Karmakar, A. Popat, M. H. Yu and C. Z. Yu, *RSC Adv.*, 2014, **4**, 709.

3   (a) M. Salem, S. Rohani and E. R. Gillies, *RSC Adv.*, 2014, **4**, 10815; (b) S. Barui, S. Saha, G. Mondal, S. Haseena and A. Chaudhuri, *Biomaterials*, 2014, **35**, 1643; (c) M. M. Yallapu, M. Jaggi and S. C. Chauhan, *Drug Discov. Today*, 2012, **17**, 71.

4   Q. Liu and B. J. Boyd, *Analyst*, 2013, **138**, 391.

5   Y. Barenholz, *J.Control. Release*, 2012, **160**, 117.

6   D. Wang, M. S. Veena, K. Stevenson, C. Tang, B. Ho, J. D. Suh, V. M. Duarte, K. F. Faull, K. Mehta, E. S. Srivatsan and M. B. Wang, *Clin. Cancer Res.*, 2008, **14**, 6228.

7   M. Hasan, N. Belhaj, H. Benachour, M. Barberi-Heyob, C. J. F. Kahn, E. Jabbari, M. Linder and E. Arab-Tehrany, *Int. J. Pharm.*, 2014, **461**, 519.

8   (a) J. Y. Liu, S. Y. Chen, L. Lv, L. Song, S. R. Guo and S. T. Huang, *Curr. Pharm. Design*, 2013, **19**, 1974; (b) Y. L. Lin, Y. K. Liu, N. M. Tsai, J. H. Hsieh, C. H. Chen, C. M. Lin and K. W. Liao, *Nanomedicine-NBM*, 2012, **8**, 318.

9   (a) A. Karewicz, D. Bielska, A. Loboda, B. Gzyl-Malcher, J. Bednar, A. Jozkowicz, J. Dulak and M. Nowakowska, *Colloids Surf. B-Biointerfaces*, 2013, **109**, 307; (b) G. H. Shin, S. K. Chung, J. T. Kim, H. J. Joung and H. J. Park, *J. Agric. Food Chem.*, 2013, **61**, 11119.

10   (a) E. Antonini, L. Bellelli, M. L. Bonacci, M. R. Bruzzesi, A. Caputo, E. Chiancone and A. Rossi-Fanelli, *Biopolymers*, 1964, **2**, 27; (b) *Biopolymers*, 1964, **2**, 35.

11   S. Ning, Q. Huang, X. Sun, C. Li, Y. Zhang, J. Li and Y.-N. Liu, *Soft Matter*, 2011, **7**, 9394.

12   K. Wagner, A. Kautz, M. Roder, M. Schwalbe, K. Pachmann, J. H. Clement and M. Schnabelrauch, *Appl. Organomet. Chem.*, 2004, **18**, 514.

13   (a) X. Q. Li, F. T. Meng, H. Guang and Z. G. Su, *J. Chem. Res.*, 2005, **2005**, 280; (b) K. M. McLean, G. Johnson, R. C. Chatelier, G. J. Beumer, J. G. Steele and H. J. Griesser, *Colloids Surf. B-Biointerfaces*, 2000, **18**, 221.

14   (a) S. S. Dhule, P. Penfornis, T. Frazier, R. Walker, J. Feldman, G. Tan, J. He, A. Alb, V. John and R. Prchampally, *Nanomedicine*, 2012, **8**, 440; (b) Y. M. Niu, X. Y. Wang, S. H. Chai, Z. Y. Chen, X. Q. An and W. G. Shen, *J. Agric. Food Chem.*, 2012, **60**, 1865.

15   H. Wang, P. Li, L. Zhang, J. Zhang, X. Ling and H. Ran, *Chin. J. Chin. Mat. Med.*, 2009, **34**, 3021.

16   M. Takahashi, S. Uechi, K. Takara, Y. Asikin and K. Wada, *J. Agric. Food Chem.*, 2009, **57**, 9141.

17   Y. Kaminaga, A. Nagatsu, T. Akiyama, N. Sugimoto, T. Yamazaki, T. Maitani, H. Mizukami, *FEBS Lett.* 2003, **555**, 311.

18   N. Puvvada, S. Rajput, B. N. P. Kumar, M. Mandal and A. Pathak, *RSC Adv.*, 2013, **3**, 2553.

19   H. Tonnesen and J. Karlsen, *Z Lebensm Unters Forsch*, 1985, **180**, 402-404.

20   L. Song, Y. Y. Shen, J. W. Hou, L. Lei, S. R. Guo and C. Y. Qian, *Colloids Surf. A-Physicochem. Eng. Asp.*, 2011, **390**, 25-32.

21   Y. Wang, M. Pan, A. Cheng, L. Lin, Y. Ho, C. Hsieh and J. Lin, *J. Pharm. Biomed. Anal.*, 1997, **15**, 1867-1876.

22   M. Hashida, M. Nishikawa, F. Yamashita and Y. Takakura, *Drug Dev. Ind. Pharm.*, 1994, **20**, 581-590.

23   R. R. Sawant and V. P. Torchilin, *Soft Matter*, 2010, **6**, 4026.

24   M. Schwalbe, N. Buske, M. Vetterlein, K. Hoffken, K. Pachmann and J. H. Clement, *Z. Phys. Chem*, 2006, **220**, 125.

25   L. Zhang, Z. Q. Qi, Q. Huang, K. Zeng, X. Sun, J. Li and Y.-N. Liu, *Colloids Surf., B-Biointerfaces*, 2014, **123**, 15.